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===================

Leprosy is caused by the well-known *Mycobacterium leprae* ([@B1]) and the newly discovered *Mycobacterium lepromatosis* ([@B2]). The bacilli differed at least 9.1% and diverged \~10 million years ago from their last common ancestor ([@B3], [@B4]). This difference contrasts with the clonal nature of worldwide *M. leprae* strains ([@B5][@B6][@B7]). Several studies have shown that *M. lepromatosis* is the long-elusive second agent of leprosy ([@B8][@B9][@B14]). The organism has been identified so far in leprosy patients from Mexico ([@B8][@B9][@B10]), Canada ([@B11]), Brazil ([@B12]), Burma ([@B12]), and Singapore ([@B13]). It is likely the dominant cause of leprosy in Mexico ([@B9]). Dual infections with both *M. lepromatosis* and *M. leprae* have been described ([@B8], [@B12], [@B13]). Like *M. leprae*, *M. lepromatosis* has not been cultivated in medium so far.

The present draft genome of *M. lepromatosis* was sequenced from strain FJ924 that was purified and enriched initially from autopsy liver tissue ([@B2], [@B3]). Due to exhaustions of the fresh organism and extracted DNA, the sequenced DNA was extracted from scraped bacilli on a glass slide smear that had been dried, stained (Kinyoun method), and archived for 6 years. The extraction yielded \~3 ng DNA by use of the QIAamp kit (Qiagen, Valencia, CA). A whole-genome library was then constructed using the KAPA kit (Kapa Biosystems, Wilmington, MA), enriched by six PCR cycles, and sequenced on the HiSeq 2000 sequencer (Illumina, San Diego, CA).

Sixty-nine million reads with paired ends were generated. The reads were filtered to remove human sequences (14 million, \~20%) and matched to the closest *M. leprae* Br4923 genome ([@B5]) with BLAST v2.2.26 ([@B14]) for enrichment and removal of contaminant bacterial DNA. The matched reads (11 million) were assembled *de novo* (Velvet v1.2.10) ([@B15]); the contigs were aligned manually and through use of Bowtie 2 v2.1.0 ([@B16]) to the *M. leprae* genome for orders, orientations, and gap closure. A tentative draft genome resulted, which was refined through GapFiller v1-10 (BaseClear BV, Leiden, The Netherlands) ([@B17]) to capture unique sequences from all the 69 million reads. Eventually, a draft genome consisting of 3,215,823 nucleotides from 39 final contigs was obtained. From the 11.5 million mapped reads, 500-fold coverage of the genome was achieved. As a quality indicator, the genome contained all 20 genes and pseudogenes (22,814-bp) that were sequenced previously from the same strain ([@B3]). This assessment and the low number of gaps hinted that this draft genome was nearly complete.

This *M. lepromatosis* genome matched \~87% overall with the *M. leprae* genome (3,268,071 nucleotides) ([@B4], [@B5]). Being also 52 kb (\~1.6%) smaller, it was likely the smallest of all mycobacterial genomes known to date. This genome should complement another draft *M. lepromatosis* genome (3,206,741 nucleotides of 126 contigs) reported several weeks earlier by a separate team ([@B18]). Decoding the genome of *M. lepromatosis* should be useful for the research and care for leprosy.

Nucleotide sequence accession numbers. {#s1}
--------------------------------------

This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession no. [LAWX00000000](LAWX00000000). The version described in this paper is version LAWX01000000.
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